Check out our latest findings on Type 1 Diabetes and how specific microRNAs could help our understanding and future treatment approaches. #Diabetes#T1DM#MicroRNAs@Innodiagroup@unisiena
https://t.co/YknfAMPTtm
‼️Individuati dai ricercatori dell'#Università di #Siena nuovi #biomarcatori per il trattamento personalizzato del #diabetemellito tipo 1.
La scoperta è stata pubblicata su “Cell Reports Medicine” nell’ambito di uno studio finanziato dall’UE e dal MUR.
👉https://t.co/IDkApRQeiy
Check out our latest findings on Type 1 Diabetes and how specific microRNAs could help our understanding and future treatment approaches. #Diabetes#T1DM#MicroRNAs@Innodiagroup@unisiena
https://t.co/YknfAMPTtm
7/ Future studies will focus on the exact mechanisms through which these miRNAs influence T1DM progression and how they can be leveraged in clinical practice. For those interested in the details, check out our full paper published in @CellRepMed https://t.co/YknfAMPTtm
Check out our latest findings on Type 1 Diabetes and how specific microRNAs could help our understanding and future treatment approaches. #Diabetes#T1DM#MicroRNAs@Innodiagroup@unisiena
https://t.co/YknfAMPTtm
6/ This research also underscores the importance of non-coding RNAs in disease management, offering new avenues for therapeutic development and better understanding of T1DM pathogenesis. 🌟
RNA is…complicated. If it’s not confusing enough that there are many types of RNA, some RNA molecules also fold into different shapes that help their stability and functions. Not to worry! We break it all down for you in our new fact sheet: https://t.co/f0bpvxV1ov
IL-22RA1 receptor has a crucial role in the pancreas. Blocking IL-22RA1 impairs insulin quality, increasing stress in human islets. Mice lacking IL-22RA1 in beta-cells show decreased insulin secretion and increased inflammation.https://t.co/bvFPXH1gvr #DiabetesResearch#IL22RA1
Happy to have contributed in this groundbreaking story led by @sumaira_hasnain,showcasing promising IL-22-targeted treatments for diabetes and liver steatosis. Check out the full details here https://t.co/bvFPXH0IFT. Don't miss the insightful tweetorial by @sumaira_hasnain below!
So glad to see our back-to-back papers out in @NatureComms today on the cytokine #IL22
Thank you to all the coauthors involved, it’s been years in the making…@MaterResearch@TRI_info @UQMedicine @QIMRB_Institute @UniMelbMDHS
Especially my #Immunopathology Team (@haresshsajiir@yau_kuan and Alexandra Mueller)
🧵Here’s what we show 👇🏼
1/n
https://t.co/ylKEdfPMF8
https://t.co/03JUYmHb0P
Thrilled to be an invited speaker at the #IDS2024 Rising Stars symposium! Join me for my lecture, "From Whispers to Shouts: The Impact of Circulating microRNAs on T1D Progression and Stratification." Can't wait to share insights with fellow experts! #Immunology#T1D@unisiena
Want to know how VISIUM, CytAssist, CosMx, Xenium and CytAssist protein compare with each other in human tumors?
Then this preprint and tweetorial are for you!
https://t.co/l0au9m085f
Autoimmune diseases are the by-product of past
evolutionary selection against environmental pathogens. It was a trade off between protection against infections (at that time) and risk of autoimmunity (present day) https://t.co/VDfzqlqPoX
Happy #DayofImmunology! 📢 Fascinated by the #immunology of #type1diabetes? Join us at #IDS2024 congress in Bruges 🇧🇪 Together, we strive to better predict, prevent and eventually cure #T1D 💪Registration and abstract submission are open NOW!👇